Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The surgeon general said the federal government is still waiting on more information to be available before they issue a recommendation.

Johnson & Johnson Booster Shot ‘Likely' Will Be Necessary, Surgeon General Says—Possibly With A Different Vaccine

AstraZeneca

Novavax

Hint: Pfizer, BioNTech, and Moderna didn't make the list.

3 Top COVID Vaccine Stocks That Wall Street Is Bullish About

Merck

My pair trade, long JNJ vs. short MRK suggestion has worked out well since December's article. Johnson & Johnson remains a smart accumulation idea, while I currently rate Merck a hold.

Revisiting My Long Johnson & Johnson Vs. Short Merck Call In 2020

NVIDIA

It might not take them all that long to reach the milestone market cap.

3 Stocks to Buy That Could Join the $1 Trillion Club

AbbVie

Pfizer

These pharmaceutical giants offer strong, dependable dividends and the size to weather the market's ups and downs.

3 Boring Healthcare Stocks Everyone Should Own

Both stocks have plenty to offer investors.

Better Dividend Stock: Johnson & Johnson or Pfizer?

Cenntro Electric Group

Pershing Square Tontine Holdings

What did the stock market do today? Cardano climbed to all-time highs.

What Did the Stock Market Do Today, Aug. 20? 3 Big Stories to Catch Up On.

Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock?

Johnson & Johnson (JNJ) Up 5.1% Since Last Earnings Report: Can It Continue?

J&J's (JNJ) CEO Alex Gorsky who has led the company for almost a decade resigns. Joaquin Duato to succeed as CEO.

J&J (JNJ) CEO Alex Gorsky to Resign, Joaquin Duato to Succeed

Shares of Johnson & Johnson (NYSE:JNJ) saw some unusual options activity on Friday. Following the unusual option alert, the stock price moved up to $179.33.

Johnson & Johnson's Big Options Activity Spotted

Johnson & Johnson's (NYSE: JNJ) CEO Alex Gorsky will step away from his role in January 2022 in favor of Joaquin Duato, the vice-chairman of the executive committee. He served as CEO for nine years and will become J&J's executive chairman effective January 3.

J&J's Alex Gorsky To Step Down As CEO, Hands Baton To Joaquin Duato

Apple

Anthem

Franklin Resources

Cisco Systems

Chevron

Home Depot

Lowe's

Altria

Microsoft

AT&T

T. Rowe Price Group

Texas Instruments

Wells Fargo

Xcel Energy

This is a quarterly review of DivGro, my portfolio of dividend growth stocks. I write these reviews to summarize investment decisions and to share portfolio statistics. The article includes charts showing DivGro's composition and how positions contribute to projected annual dividend income.

Quarterly Review Of DivGro: Q2-2021

Alex Gorsky, 61, cited family health issues as the reason. He will be succeeded by his longtime lieutenant, Joaquin Duato.

J&J's CEO Is Stepping Aside

Johnson & Johnson said Thursday that Joaquin Duato will transition to the role of CEO on January 3, replacing Alex Gorsky.

Johnson & Johnson names Joaquin Duato as its next CEO

Joaquin Duato, the vice chairman of Johnson & Johnson's executive committee, will step up as the company's next CEO and a member of its board of directors effective Jan. 3, 2022.

Johnson & Johnson CEO stepping down in January

Johnson & Johnson JNJ, +0.78% said late Thursday that Joaquin Duato, vice chairman of the company's executive committee, will become CEO on Jan. 3, with Chairman and Chief Executive Alex Gorsky transitioning to executive chairman. Duato will also be appointed as a member of the board of directors, Johnson & Johnson said.

Johnson & Johnson CEO Gorsky to step down, become executive chairman

Johnson & Johnson said on Thursday its Vice Chairman of Executive Committee Joaquin Duato will become chief executive officer from Jan. 3, replacing Alex Gorsky who has been at the helm for nine years.

J&J says veteran Duato to replace Gorsky as chief executive

Johnson & Johnson announced Thursday evening that Joaquin Duato will become the company's new CEO effective January 3, replacing current chairman and CEO Alex Gorsky.

J&J names Joaquin Duato as CEO effective January 3, replacing Alex Gorsky

NEW BRUNSWICK, N.J., Aug. 19, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that Mr.

Alex Gorsky to Serve as Executive Chairman and Transition Role of Chief Executive Officer of Johnson & Johnson to Joaquin Duato, Effective January 3, 2022

Johnson & Johnson (NYSE: JNJ) COVID-19 vaccines bottled and packaged at Aspen's site meant for Africa are exported to the European Union, the New York Times reported earlier this week.  Even though South Africa ordered 31 million doses of J&J's shot back in April, the country is still waiting to receive the bulk of its order, the Times reported on Monday.

Europe Faces Backlash For Importing JNJ COVID-19 Shots From South Africa: Reuters

Janssen, a unit of Johnson & Johnson (NYSE: JNJ), announced preliminary data from the Phase 1 CHRYSALIS study evaluating Rybrevant (amivantamab-vmjw) for non-small cell lung cancer (NSCLC) with mesenchymal-epithelial transition (MET) exon 14 skipping (METex14) mutations. A total of 19 patients with METex14 mutations received either a high or low dose of Rybrevant, and 14 of them were evaluable.

Johnson & Johnson Touts Rybrevant Label Expansion After Rare Lung Cancer Approval

BioNTech SE

Moderna

In order to provide better protection to the American people from rising COVID-19 cases due to the surge of the Delta variant, U.S. health officials are recommending use of a booster dose for individuals starting this fall.

US Set to Receive COVID-19 Vaccine Booster Dose Next Month

The stock price of ​Johnson & Johnson (NYSE: JNJ) has seen a rise of over 7% over the last twenty-one trading days, and it is also up 15% year-to-date. Note that such a move for JNJ stock is uncommon, and it has occurred less than 90 times over the last 10 years.

Will The Gains Continue For Johnson & Johnson Stock After A 7% Rise In A Month?

A new South African study shows the one-dose vaccine is highly effective against the delta variant.

Here's Why Johnson & Johnson's Vaccine Could Overtake Both Pfizer and Moderna

American Express

Goldman Sachs

Harvard Bioscience

Honeywell

JPMorgan Chase & Co

Procter & Gamble

Two new Breakout Stocks for Week 32 with better than 10% short-term upside potential. The ETF/ETN forecast section now goes out in a separate article. Following the Momentum Gauges®, the portfolio is up +49.8% YTD with a record 18 out of 32 weeks this year in negative market conditions above the 40 MG level.

News for Johnson & Johnson Stock (JNJ)